Biotech Values

[scott2987]

(OT) Re Conjuchem

Further note on GLP-1. They mentioned on CNBC today in addition to diabetes it is now showing some promise in obesity. This would seem to give CJC another opportunity to partner in large indication piggybacking on others work. The potential advantage of once or twice per week dosing vs. once or twice per day would seem significant.
Do not know answer to your question.